Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial

Launched by JONSSON COMPREHENSIVE CANCER CENTER · May 28, 2025

Keywords

ClinConnect Summary

The ILLUSION Trial is studying a new way to treat localized prostate cancer using a technique called computed tomography (CT)-guided stereotactic body radiation therapy (SBRT). This approach uses special imaging to precisely target the prostate while monitoring its movement during treatment. The goal is to minimize side effects, particularly those affecting urinary and bowel function, while effectively treating the cancer. SBRT delivers radiation in smaller doses over several days, which helps protect healthy tissue around the tumor.

To participate in this trial, you need to be an adult male with confirmed localized prostate cancer that hasn't spread to other areas of the body. You should not have had previous treatments like certain types of surgery or radiation for prostate cancer. If you decide to join, you will receive careful monitoring and support throughout the trial. It’s important to know that this trial is not yet recruiting participants, but it aims to offer a promising option for patients managing localized prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed, clinically localized adenocarcinoma of the prostate
• • No evidence of metastatic disease in lymph nodes above the bifurcation of the renal arteries, or in bones or visceral organs (nodal disease identified on a prostate-specific membrane antigen \[PSMA\] positron emission tomography \[PET\]/CT scan below the bifurcation of the renal arteries are amenable)
• • Staging workup as recommended by the National Comprehensive Cancer Network (NCCN) on the basis of risk grouping
• • Advanced imaging studies (i.e. PSMA PET/CT and fluciclovine PET/CT scan) can supplant a bone scan if performed first
• • Age ≥ 18
• • Written informed consent obtained from participant or participant's legal representative and ability for participant to comply with the requirements of the study
• Exclusion Criteria:
• • Patients with neuroendocrine or small cell carcinoma of the prostate
• • Patients with any evidence of distant metastases except that evidence of lymphadenopathy below the level of the renal arteries can be deemed locoregional per the discretion of the investigator
• • Prior whole gland cryosurgery, high-intensity focused ultrasound (HIFU) or brachytherapy of the prostate
• • Prior pelvic radiotherapy
• • History of Crohn's Disease, ulcerative colitis, or ataxia telangiectasia
• • Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the participant or the quality of the data